BioSpace News Archive

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance® (empagliflozin) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced today that the Company has acquired majority ownership of Biotech Laboratories U.S.A. LLC (“Biotech”).

InMode Ltd. today announced that management will participate in the following upcoming conferences: Baird Global Healthcare Conference

Inspira Technologies today announced that Joe Hayon , the Company’s Co-Founder and Chief Financial Officer, will participate virtually in the following upcoming conferences: H.C. Wainwright 23rd Annual Global Investment Conference

Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021 at 2:00 p.m. Eastern Time.

Today, the American Urological Association (AUA), in partnership with the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) released the 2021 clinical guideline for the diagnosis, evaluation, treatment and follow-up of Neurogenic Lower Urinary Tract Dysfunction (NLUTD) in adults.

Boston Scientific Corporation will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30 a.m. – 12:30 p.m. EDT.

Positive results from the POSEIDON Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), and tremelimumab, when added to platinum-based chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).

Anthony Tennyson’s, Chief Executive Officer of Awakn Life Sciences, corporate presentation will be available on-demand starting Monday, September 13th at 7:00 a.m. ET. To attend please register here.

US Medical Innovations, LLC (USMI), a U.S. FDA-registered life-science and biomedical device company and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that Jerome Canady MD, CEO will be presenting at the Baird Global Healthcare Conference on Tuesday, September 14th from 10:15 to 10:45 AM ET.